Home LiteratureArticle Details
PMID: 20335067 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Mesenchymal stem cell therapy: Two steps forward, one step back.

Trends in molecular medicine ·Vol. 16 ·No. 5 ·2010-05-00 ·Pages 203-9

Ankrum J, Karp JM

Abstract

Mesenchymal stem cell (MSC) therapy is poised to establish a new clinical paradigm; however, recent trials have produced mixed results. Although MSC were originally considered to treat connective tissue defects, preclinical studies revealed potent immunomodulatory properties that prompted the use of MSC to treat numerous inflammatory conditions. Unfortunately, although clinical trials have met safety endpoints, efficacy has not been demonstrated. We believe the challenge to demonstrate efficacy can be attributed in part to an incomplete understanding of the fate of MSC following infusion. Here, we highlight the clinical status of MSC therapy and discuss the importance of cell-tracking techniques, which have advanced our understanding of the fate and function of systemically infused MSC and might improve clinical application.

MeSH Terms
Animals Humans Mesenchymal Stem Cell Transplantation Mesenchymal Stem Cells/cytology,physiology
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Ankrum James
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard Stem Cell Institute, Harvard-MIT Division of Health Sciences and Technology 65 Landsdowne Street, Cambridge, MA 02139, USA.
Karp Jeffrey M
References (51)
51 references, click to expand
  1. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells.
    Gene Ther. 2008 May;15(10):730-8 PMID: 18401438
  2. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.
    Blood. 2002 May 15;99(10):3838-43 PMID: 11986244
  3. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction.
    Circulation. 2003 May 13;107(18):2290-3 PMID: 12732608
  4. Fate of culture-expanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics.
    Circ Res. 2009 Feb 13;104(3):398-402 PMID: 19096027
  5. TSG-6: a pluripotent inflammatory mediator?
    Biochem Soc Trans. 2006 Jun;34(Pt 3):446-50 PMID: 16709183
  6. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.
    Lancet. 2008 May 10;371(9624):1579-86 PMID: 18468541
  7. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6.
    Cell Stem Cell. 2009 Jul 2;5(1):54-63 PMID: 19570514
  8. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion.
    Cells Tissues Organs. 2001;169(1):12-20 PMID: 11340257
  9. Seeding efficiency of primitive human hematopoietic cells in nonobese diabetic/severe combined immune deficiency mice: implications for stem cell frequency assessment.
    Blood. 1999 Nov 1;94(9):3055-61 PMID: 10556189
  10. The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice.
    Blood. 2009 Jan 22;113(4):816-26 PMID: 18818395
  11. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production.
    Nat Med. 2009 Jan;15(1):42-9 PMID: 19098906
  12. Labeling of mesenchymal stem cells by bioconjugated quantum dots.
    Nano Lett. 2007 Oct;7(10):3071-9 PMID: 17887799
  13. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury.
    Am J Physiol Renal Physiol. 2007 May;292(5):F1626-35 PMID: 17213465
  14. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche.
    Nature. 2009 Jan 1;457(7225):92-6 PMID: 19052546
  15. Regenerating the heart.
    Nat Biotechnol. 2005 Jul;23(7):845-56 PMID: 16003373
  16. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.
    J Am Coll Cardiol. 2009 Dec 8;54(24):2277-86 PMID: 19958962
  17. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity.
    Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14022-7 PMID: 19666564
  18. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells.
    J Cell Physiol. 2007 Apr;211(1):27-35 PMID: 17226788
  19. Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis.
    Fibrogenesis Tissue Repair. 2008 Oct 13;1(1):4 PMID: 19014650
  20. Immunomodulatory properties of mesenchymal stromal cells.
    Blood. 2007 Nov 15;110(10):3499-506 PMID: 17664353
  21. Fibroblast precursors in normal and irradiated mouse hematopoietic organs.
    Exp Hematol. 1976 Sep;4(5):267-74 PMID: 976387
  22. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial.
    Circulation. 2006 Mar 14;113(10):1287-94 PMID: 16520413
  23. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells.
    Blood. 2006 Dec 1;108(12):3938-44 PMID: 16896152
  24. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.
    Blood. 2003 May 1;101(9):3722-9 PMID: 12506037
  25. Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging.
    Stem Cells. 2009 Jul;27(7):1548-58 PMID: 19544460
  26. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment.
    Nature. 2005 Jun 16;435(7044):969-73 PMID: 15959517
  27. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy.
    Eur Heart J. 2009 Nov;30(22):2722-32 PMID: 19586959
  28. Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction.
    Chin Med J (Engl). 2004 Oct;117(10):1443-8 PMID: 15498362
  29. Optimizing mesenchymal stem cell-based therapeutics.
    Curr Opin Biotechnol. 2009 Oct;20(5):531-6 PMID: 19783424
  30. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment.
    Biochem Biophys Res Commun. 2007 Mar 16;354(3):700-6 PMID: 17257581
  31. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.
    Lancet. 2004 May 1;363(9419):1439-41 PMID: 15121408
  32. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution.
    Circulation. 2003 Aug 19;108(7):863-8 PMID: 12900340
  33. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.
    Cytotherapy. 2006;8(4):315-7 PMID: 16923606
  34. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views.
    Stem Cells. 2007 Nov;25(11):2896-902 PMID: 17901396
  35. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging.
    Stem Cells. 2009 Oct;27(10):2614-23 PMID: 19650040
  36. Imaging molecular expression on vascular endothelial cells by in vivo immunofluorescence microscopy.
    Mol Imaging. 2006 Jan-Mar;5(1):31-40 PMID: 16779968
  37. Bone marrow cell trafficking following intravenous administration.
    Br J Haematol. 1999 Dec;107(4):895-902 PMID: 10606901
  38. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury.
    Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11002-7 PMID: 17569781
  39. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms.
    Mol Ther. 2009 Jun;17(6):939-46 PMID: 19337235
  40. Mesenchymal stem cells: revisiting history, concepts, and assays.
    Cell Stem Cell. 2008 Apr 10;2(4):313-9 PMID: 18397751
  41. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts.
    Nat Med. 2003 Sep;9(9):1195-201 PMID: 12910262
  42. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone.
    Nat Med. 2008 Feb;14(2):181-7 PMID: 18193058
  43. Mesenchymal stem cell homing: the devil is in the details.
    Cell Stem Cell. 2009 Mar 6;4(3):206-16 PMID: 19265660
  44. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture.
    Leukemia. 2003 Jan;17(1):160-70 PMID: 12529674
  45. A novel secretory tumor necrosis factor-inducible protein (TSG-6) is a member of the family of hyaluronate binding proteins, closely related to the adhesion receptor CD44.
    J Cell Biol. 1992 Jan;116(2):545-57 PMID: 1730767
  46. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction.
    Circulation. 2005 Sep 6;112(10):1451-61 PMID: 16129797
  47. Distribution of circulation-derived endothelial progenitors following systemic delivery.
    Endothelium. 2007 Jan-Feb;14(1):1-5 PMID: 17364891
  48. Stem cell transplantation: the lung barrier.
    Transplant Proc. 2007 Mar;39(2):573-6 PMID: 17362785
  49. Why are MSCs therapeutic? New data: new insight.
    J Pathol. 2009 Jan;217(2):318-24 PMID: 19023885
  50. Mesenchymal stem cells and their potential as cardiac therapeutics.
    Circ Res. 2004 Jul 9;95(1):9-20 PMID: 15242981
  51. Mesenchymal stem cells reside in virtually all post-natal organs and tissues.
    J Cell Sci. 2006 Jun 1;119(Pt 11):2204-13 PMID: 16684817
Article Info
Journal
Trends in molecular medicine
Abbr.
Trends Mol Med
ISSN
1471-499X
DOI
10.1016/j.molmed.2010.02.005
Published
2010-05-00
Epub
2010-00-23
Pages
203-9
Language
English
Region
England
NLM ID
100966035
PMCID
PMC2881950
Subset
IM
Grants
NIDCR NIH HHS · R03 DE019191 · United States
NIGMS NIH HHS · R01 GM086433 · United States
NIDCR NIH HHS · DE019191 · United States
NHLBI NIH HHS · R01 HL095722 · United States
NIDCR NIH HHS · R03 DE019191-01A1 · United States
External Links
PubMed source DOI: 10.1016/j.molmed.2010.02.005 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2